FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2091401607> ?p ?o ?g. }

• W2091401607 endingPage "267" @default.
• W2091401607 startingPage "259" @default.
• W2091401607 abstract "Background We studied whether hepatitis B surface antigen (HBsAg)/anti-HBs immune complex levels in chronic hepatitis B (CHB) patients receiving antiviral therapy could be used as a response marker at baseline (BL) or early during treatment to predict treatment outcome. Methods An experimental array-based assay (immunological multi-parameter chip technology [IMPACT]; Roche Diagnostics, Penzberg, Germany) served to determine HBsAg, anti-HBs and complex levels. We tested a panel of serum samples of 40 hepatitis B e antigen (HBeAg)-positive and 44 HBeAg-negative patients who received pegylated interferon and adefovir for 48 weeks. Results HBsAg loss occurred in 4 of 40 HBeAg-positive and 4 of 44 HBeAg-negative patients. A total of 14 of 40 HBeAg-positive patients lost HBeAg and 12 of them formed anti-HBe. At BL, complexes were present in 83 (99%) patients, whereas free anti-HBs levels were detectable in 5 patients. Complex levels at BL and week 12 were higher in HBeAg-positive patients with HBeAg loss, compared to patients who retained HBeAg ( P=0.002 and P=0.005, respectively). Receiver operating characteristic analysis for HBeAg loss in HBeAg-positive patients at BL and week 12 showed area-under-the-curve values of 0.79 ( P=0.002) and 0.82 ( P=0.003) for complex levels. We found no correlation in either HBeAg-positive or -negative patients between complex levels and HBsAg loss. Conclusions We demonstrated for the first time that before and during treatment HBsAg/anti-HBs immune complex levels can predict HBeAg loss in HBeAg-positive CHB patients treated with pegylated interferon and adefovir. Complexes were present in almost all patients at BL and were higher in patients who lost HBeAg. In conclusion, determining HBsAg/anti-HBs immune complex levels before and early during treatment could aid in selecting CHB patients with an optimal chance to achieve HBeAg loss." @default.
• W2091401607 created "2016-06-24" @default.
• W2091401607 creator A5013964835 @default.
• W2091401607 creator A5026988384 @default.
• W2091401607 creator A5043345253 @default.
• W2091401607 creator A5043626370 @default.
• W2091401607 creator A5045491291 @default.
• W2091401607 creator A5060768578 @default.
• W2091401607 creator A5068267699 @default.
• W2091401607 creator A5086825373 @default.
• W2091401607 creator A5091240947 @default.
• W2091401607 date "2013-04-01" @default.
• W2091401607 modified "2023-09-25" @default.
• W2091401607 title "Experimental Hbsag/Anti-Hbs Complex Assay for Prediction of Hbeag Loss in Chronic Hepatitis B Patients Treated with Pegylated Interferon and Adefovir" @default.
• W2091401607 cites W1545139625 @default.
• W2091401607 cites W1809351441 @default.
• W2091401607 cites W1978921235 @default.
• W2091401607 cites W1987631597 @default.
• W2091401607 cites W1998881478 @default.
• W2091401607 cites W2000635340 @default.
• W2091401607 cites W2004832653 @default.
• W2091401607 cites W2005330444 @default.
• W2091401607 cites W2008643979 @default.
• W2091401607 cites W2016344397 @default.
• W2091401607 cites W2023718741 @default.
• W2091401607 cites W2031317669 @default.
• W2091401607 cites W2033837061 @default.
• W2091401607 cites W2067109440 @default.
• W2091401607 cites W2070857448 @default.
• W2091401607 cites W2082534929 @default.
• W2091401607 cites W2086037121 @default.
• W2091401607 cites W2090919575 @default.
• W2091401607 cites W2094798000 @default.
• W2091401607 cites W2098459535 @default.
• W2091401607 cites W2101032357 @default.
• W2091401607 cites W2116118057 @default.
• W2091401607 cites W2146594318 @default.
• W2091401607 cites W2395564105 @default.
• W2091401607 cites W4211026375 @default.
• W2091401607 doi "https://doi.org/10.3851/imp2707" @default.
• W2091401607 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24256626" @default.
• W2091401607 hasPublicationYear "2013" @default.
• W2091401607 type Work @default.
• W2091401607 sameAs 2091401607 @default.
• W2091401607 citedByCount "11" @default.
• W2091401607 countsByYear W20914016072015 @default.
• W2091401607 countsByYear W20914016072016 @default.
• W2091401607 countsByYear W20914016072018 @default.
• W2091401607 countsByYear W20914016072019 @default.
• W2091401607 countsByYear W20914016072020 @default.
• W2091401607 countsByYear W20914016072022 @default.
• W2091401607 crossrefType "journal-article" @default.
• W2091401607 hasAuthorship W2091401607A5013964835 @default.
• W2091401607 hasAuthorship W2091401607A5026988384 @default.
• W2091401607 hasAuthorship W2091401607A5043345253 @default.
• W2091401607 hasAuthorship W2091401607A5043626370 @default.
• W2091401607 hasAuthorship W2091401607A5045491291 @default.
• W2091401607 hasAuthorship W2091401607A5060768578 @default.
• W2091401607 hasAuthorship W2091401607A5068267699 @default.
• W2091401607 hasAuthorship W2091401607A5086825373 @default.
• W2091401607 hasAuthorship W2091401607A5091240947 @default.
• W2091401607 hasConcept C126322002 @default.
• W2091401607 hasConcept C147483822 @default.
• W2091401607 hasConcept C203014093 @default.
• W2091401607 hasConcept C2522874641 @default.
• W2091401607 hasConcept C2775940106 @default.
• W2091401607 hasConcept C2776461080 @default.
• W2091401607 hasConcept C2777382497 @default.
• W2091401607 hasConcept C2777410769 @default.
• W2091401607 hasConcept C2777869810 @default.
• W2091401607 hasConcept C2779517838 @default.
• W2091401607 hasConcept C2780040827 @default.
• W2091401607 hasConcept C2780593183 @default.
• W2091401607 hasConcept C3020491458 @default.
• W2091401607 hasConcept C71924100 @default.
• W2091401607 hasConcept C90924648 @default.
• W2091401607 hasConceptScore W2091401607C126322002 @default.
• W2091401607 hasConceptScore W2091401607C147483822 @default.
• W2091401607 hasConceptScore W2091401607C203014093 @default.
• W2091401607 hasConceptScore W2091401607C2522874641 @default.
• W2091401607 hasConceptScore W2091401607C2775940106 @default.
• W2091401607 hasConceptScore W2091401607C2776461080 @default.
• W2091401607 hasConceptScore W2091401607C2777382497 @default.
• W2091401607 hasConceptScore W2091401607C2777410769 @default.
• W2091401607 hasConceptScore W2091401607C2777869810 @default.
• W2091401607 hasConceptScore W2091401607C2779517838 @default.
• W2091401607 hasConceptScore W2091401607C2780040827 @default.
• W2091401607 hasConceptScore W2091401607C2780593183 @default.
• W2091401607 hasConceptScore W2091401607C3020491458 @default.
• W2091401607 hasConceptScore W2091401607C71924100 @default.
• W2091401607 hasConceptScore W2091401607C90924648 @default.
• W2091401607 hasIssue "3" @default.
• W2091401607 hasLocation W20914016071 @default.
• W2091401607 hasLocation W20914016072 @default.
• W2091401607 hasOpenAccess W2091401607 @default.
• W2091401607 hasPrimaryLocation W20914016071 @default.
• W2091401607 hasRelatedWork W1998881478 @default.
• W2091401607 hasRelatedWork W2067743113 @default.

• next